http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Precipio's (PRPO) Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
-
Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
-
Precipio (PRPO) Shares Growth Catalysts For HemeScreen
-
Precipio Shares Growth Catalysts For HemeScreen
-
Precipio Announces Q1-2023 Shareholder Update Call
-
Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division
-
Precipio Signs Another HemeScreen™ Customer
-
Precipio (PRPO) Granted 180-day Extension From NASDAQ To Regain Compliance
-
Precipio Granted 180-day Extension From NASDAQ To Regain Compliance
-
Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined
-
Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call
-
Precipio Ships First IV-Cell® Order to Major US Healthcare System
-
CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers
-
Precipio (PRPO) continues to sign up and onboard HemeScreen customers
-
Precipio continues to sign up and onboard HemeScreen™ customers
-
ThermoFisher Salesforce Votes Precipio’s HemeScreen® as “Best New Product”
-
Precipio Signs Another Major HemeScreen™ Customer
-
Precipio (PRPO) Signs Additional Major HemeScreen Customer
-
Precipio Signs Additional Major HemeScreen™ Customer
-
Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference
-
Precipio Announces Third Quarter Shareholder Update Call
-
Precipio (PRPO) Enters Agreement with Another Major US Healthcare Distributor for HemeScreen
-
Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™
-
Sharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital Sales
-
Precipio Launches New 1-Step Technology for all HemeScreen Assays
-
Toni-Ann Mills Joins Precipio’s Products Division to Lead Channel Partner Training, Learning & Development
-
Precipio Announces Second Quarter Shareholder Update Call
-
Precipio to distribute HemeScreen® through Fisher Healthcare channel
-
Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote
-
Keith Meadors Joins Precipio to Lead its Products Division
-
Precipio (PRPO) Receives CE-IVD Certification to Market Multiple HemeScreen Panels in Europe
-
Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe
-
Precipio Signs First IV-Cell Customer Agreement
-
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
-
Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call
-
Precipio (PRPO) Announces CFO Resignation, Appoints Matt Gage as Interim CFO
-
Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO
-
Precipio (PRPO) Reports Prelim 2021 Revenue of $8.9M
-
Precipio Releases Year-End 2021 Preliminary Unaudited Results and Outlook for 2022
-
New York State Approves Precipio’s HemeScreen for POL clinical use
-
Precipio Announces Q3-2021 and year-end Shareholder Update Call
-
American Oncology Network Partners with Precipio to Bring HemeScreen® into AON’s Laboratory
-
Precipio Reschedules Q2-2021 Shareholder Update Call
-
Precipio Corrects Announcement of Q2-2021 Shareholder Update Call
-
Precipio Announces Q2-2021 and year-end Shareholder Update Call
-
Precipio Announces Preliminary Unaudited Q2-2021 Revenues of $2.3M
-
Precipio (PRPO) Terminates its Equity Line
-
Precipio Terminates its Equity Line
-
Precipio Launches HemeScreen® Anemia Panel, a One-of-its-Kind Testing Tool
-
Precipio Announces Q1-2021 and year-end Shareholder Update Call

